Title: Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial
Authors: Zinman, Bernard ×
Fulcher, Greg
Rao, Paturi V
Thomas, Nihal
Endahl, Lars A
Johansen, Thue
Lindh, Rebecka
Lewin, Andrew
Rosenstock, Julio
Pinget, Michel
Mathieu, Chantal #
Issue Date: Mar-2011
Publisher: The Lancet Publishing Group
Series Title: The Lancet vol:377 issue:9769 pages:924-31
Abstract: Insulin degludec is a new basal insulin that forms soluble multihexamer assemblies after subcutaneous injection, resulting in an ultra-long action profile. This study aimed to assess efficacy and safety of insulin degludec injected once a day or three times a week compared with insulin glargine once a day in insulin-naive people with type 2 diabetes, who were inadequately controlled with oral antidiabetic drugs.
ISSN: 0140-6736
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science